Mineralys Therapeutics, Inc., a private, clinical-stage biopharmaceutical company founded by Catalys Pacific committed to developing best-in-class, novel therapy for the treatment of hypertension. The Company is driven to bring a targeted approach to the management of hypertension via the development of MLS-101. MLS-101, licensed from Mitsubishi Tanabe Pharma Corporation, is a highly selective and potent aldosterone synthase inhibitor that is being investigated for the treatment of hypertension.

NewSpring partners with the innovators, makers, and operators of high-performing companies in dynamic industries to catalyze new growth and seize compelling opportunities.

Safeguard Scientifics builds value in high-growth, revenue-stage information technology and life sciences businesses. The company provides growth capital, as well as a wide range of strategic, operational and management resources to strategic partners. It participates in expansion financings, management buyouts, recapitalizations, industry consolidations and early-stage activities. Safeguard Scientifics has established strategic relationships with Cambridge Technology Partners, Novell and Internet Capital Group. The company focuses on time-to-volume entities. It maintains interests in Acsis, Alliance Consulting, Clarient, Emerge Interactive, Laureate Pharma, Mantas, Neuronyx, NexTone Communications and Ventaira Pharmaceutical. Safeguard Scientifics has operated for more than 50 years and is headquartered in Wayne, Pa.